Literature DB >> 19514733

Na+ currents in cardioprotection: better to be late.

Bruno Le Grand1, Christophe Pignier, Robert Létienne, Francis Colpaert, Florence Cuisiat, Françoise Rolland, Agnes Mas, Maud Borras, Bernard Vacher.   

Abstract

We report the discovery of a selective, potent inhibitor of the late current mediated by the cardiac isoform of the sodium channel (Na(V)1.5). The compound, 3,4-dihydro-N-[(2S)-3-[(2-hydroxy-3-methylphenyl)thio]-2-methylpropyl]-2H-(3R)-1,5-benzoxathiepin-3-amine (2d) (F 15741), blocks the late component of the Na(+) currents and greatly reduces veratridine- or ischemia-induced contracture in isolated tissue and whole heart. The cardioprotective action of 2d was further established in a model of myocardial infarction in the pig in which 2d prevents ischemia-reperfusion damage after 60 min of coronary occlusion and 48 h reperfusion. Under these experimental conditions, only 2d and cariporide reduce infarct size. Remarkably, myocardial protection afforded by 2d occurs in the absence of hemodynamic effects. These data expand the therapeutic potential of late I(Na) blockers and suggest that 2d could be useful in pathologies for which pharmacological treatments are not yet available.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19514733     DOI: 10.1021/jm900296e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

Review 1.  Ranolazine: a new approach to treating an old problem.

Authors:  Bharath M Reddy; Howard S Weintraub; Arthur Z Schwartzbard
Journal:  Tex Heart Inst J       Date:  2010

2.  The novel late Na+ current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparations.

Authors:  Sridharan Rajamani; Gongxin Liu; Nesrine El-Bizri; Donglin Guo; Cindy Li; Xiao-Liang Chen; Kristopher M Kahlig; Nevena Mollova; Elfatih Elzein; Jeff Zablocki; Luiz Belardinelli
Journal:  Br J Pharmacol       Date:  2016-09-14       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.